Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
SPCX$132.07-3.85(-2.83%)Stack Capital Group Inc. Reports Q3-2026 Financial Results7:45:00 AM ETCOP$138.49+1.55(+1.13%)BUZZ-ConocoPhillips rises on Q3 profit beat7:40:48 AM ETTGT$164.75+1.70(+1.04%)Target Looks More Attractive Than You'd Think7:31:07 AM ETCOP$138.49+1.55(+1.13%)UPDATE 2-ConocoPhillips beats estimates on higher oil prices, raises dividend7:30:23 AM ETCOP$138.49+1.55(+1.13%)ConocoPhillips Q3 profit beats on higher prices, hikes dividend7:26:13 AM ETMETA$637.14+7.14(+1.13%)UPDATE 2-Meta sells first bonds in euros, raises €9 billion7:25:25 AM ETDTE$137.45-0.06(-0.04%)UPDATE 1-DTE Energy to sell its non-utility business for about $3 billion7:23:30 AM ETAAPL$352.27+2.76(+0.79%)Jim Cramer's Surprise Midterm Winner: Apple, Because Fewer Data Centers Could Mean Cheaper Memory7:19:09 AM ETTSLA$376.70-8.49(-2.20%)Ferrari vs. Tesla: Can the Luce Outsell the Roadster?7:18:00 AM ETMU$756.01-39.45(-4.96%)Could Buying Micron Stock Today Help Set You Up for Life?7:17:00 AM ETMSFT$556.48+0.68(+0.12%)Microsoft Is Executing an Irreproducible Balance-Sheet-Backed Infrastructure Pre-Sale at Scale7:15:58 AM ETAAPL$352.27+2.76(+0.79%)Apple Vs. Tesla: Low CapEx Only Matters if Non-Cyclical Cash Flows Come With It7:15:57 AM ETIREN$20.90-0.80(-3.69%)IREN is Only Fit for a Specific Investor Currently7:15:22 AM ETCOP$138.49+1.55(+1.13%)BRIEF-Conocophillips Q3 Adjusted EPS USD 3.27 Vs. IBES Estimate USD 2.977:13:20 AM ETMU$756.01-39.45(-4.96%)Micron Just Closed Below $800 for the First Time Since July7:12:48 AM ETAAPL$352.27+2.76(+0.79%)Amazon, Apple, FTAI Aviation And A Basic Material Stock: CNBC's ‘Final Trades'7:12:08 AM ETCOP$138.49+1.55(+1.13%)ConocoPhillips beats profit estimates, boosts quarterly dividend7:11:13 AM ETCRWD$233.20-7.80(-3.24%)Too Late to Buy CrowdStrike Stock? Here's the 1 Thing to Watch.7:10:00 AM ETGOOG$289.36+2.06(+0.72%)These 6 Stocks Make Up a Big Share of the S&P 5007:09:00 AM ETCOP$138.49+1.55(+1.13%)UPDATE 1-ConocoPhillips beats profit estimates, boosts quarterly dividend7:07:07 AM ETLLY$1,433.10+14.96(+1.05%)Iconic California Brand, French Florist, Celebrates Grand Opening of First Indiana Location7:07:00 AM ETCVS$80.93+0.94(+1.18%)ProjectLeo, the First Private AI Health Platform to Declare Independence From Big Tech7:04:00 AM ETCOP$138.49+1.55(+1.13%)ConocoPhillips beats quarterly profit estimates7:01:40 AM ETCOP$138.49+1.55(+1.13%)ConocoPhillips announces third-quarter 2026 results and increases quarterly ordinary dividend by 11%7:00:05 AM ET

CCCC · NASDAQ

C4 Therapeutics, Inc.

$3.23 +0.11 (+3.53%)

Company overview

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in a Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$397M
Employees
110
Headquarters
Watertown, MA
Website
c4therapeutics.com
CEO
Andrew J. Hirsch
Listed
October 2, 2020
P/E
-2.71
Dividend yield
0.00%

Company financials

Revenue
$34.9M
Gross profit
$33.1M
Operating income
-$114M
EBITDA
-$108M
Net income
-$104M
EPS
-$1.19
Total assets
$329M
Total debt
$58.4M
Gross margin
94.83%
Net margin
-297.76%
Earnings yield
-36.84%

Price chart

2.493.183.884.585.27
CCCC 1D NASDAQ O3.36H3.39L3.02C3.12-0.09 (-2.80%)Vol1.72M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CCCCC4 Therapeutics, Inc. Stock news C4 Therapeutics Q3 loss per share smaller than expected as R&D costs drop Reuters
CCCCC4 Therapeutics, Inc. Stock news BRIEF-C4 Therapeutics Q3 EPS USD -0.16 Vs. IBES Estimate USD -0.2 Reuters
CCCCC4 Therapeutics, Inc. Press release C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire
CCCCC4 Therapeutics, Inc. Press release C4 Therapeutics to Participate in Upcoming November Investor Conferences GlobeNewswire
CCCCC4 Therapeutics, Inc. Stock news BRIEF-C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) Reuters
CCCCC4 Therapeutics, Inc. Press release C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
CCCCC4 Therapeutics, Inc. Stock news C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks Investment Research
CCCCC4 Therapeutics, Inc. Press release C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders GlobeNewswire
CCCCC4 Therapeutics, Inc. Stock news Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC) Financial Survey Defense World
CCCCC4 Therapeutics, Inc. Press release Insmed Appoints Two New Directors to Its Board Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to... PR Newswire
CCCCC4 Therapeutics, Inc. Stock news Reviewing ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC) Defense World
CCCCC4 Therapeutics, Inc. Press release C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual. GlobeNewswire
CCCCC4 Therapeutics, Inc. Stock news Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? Zacks Investment Research
CCCCC4 Therapeutics, Inc. Press release C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annua. GlobeNewswire
CCCCC4 Therapeutics, Inc. Stock news Financial Review: C4 Therapeutics (NASDAQ:CCCC) and Alkermes (NASDAQ:ALKS) Defense World
CCCCC4 Therapeutics, Inc. Stock news Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice Zacks Investment Research
CCCCC4 Therapeutics, Inc. Stock news C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates Zacks Investment Research
CCCCC4 Therapeutics, Inc. Stock news Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year? Zacks Investment Research
CCCCC4 Therapeutics, Inc. Stock news C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout Seeking Alpha
CCCCC4 Therapeutics, Inc. Stock news C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock? Zacks Investment Research
See more
FAQ

Questions about C4 Therapeutics, Inc.

What does C4 Therapeutics, Inc. do?
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in a Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.
What is CCCC's market cap?
C4 Therapeutics, Inc. (CCCC) is a listed stock with a live quote. The latest market cap on this page is $397M.
Where is C4 Therapeutics, Inc. headquartered?
C4 Therapeutics, Inc. is headquartered in Watertown, MA.
How do I get CCCC news from the API?
Call GET /v1/news?tickers=CCCC. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does CCCC news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CCCC, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the CCCC price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs